Skip to main content

Table 4 Clinical outcomes of patients(Group 1: Early treatment with FPV and HQ, Group 2: Late treatment with FPV and HQ, Group 3: Treatment with only HQ)

From: Benefits of treatment with favipiravir in hospitalized patients for COVID-19: a retrospective observational case–control study

Clinic outcomes Group 1 Group 2 Group 3 p-value
ARDS 6a (12.5%) 10b (20.8%) 0a,b (0.0%) 0.005a
0.005b
ICU 13c (27.1%) 13d (27.1%) 1c,d (2.1%) 0.001c
0.001d
Intubation 2 (4.2%) 4 (8.3%) 0 (0.0%) NS
Death 2 (4.2%) 4 (8.3%) 0 (0.0%) NS
  1. Statistically significant values are presented in bold. Superscript letters define the significant p-values of pairwise comparisons. Tukey's test and Games Howell tests were preferred as posthoc tests
  2. ARDS acute respiratory distress syndrome; ICU ıntensive care unit
  3. a denotes the comparison of patients with ARDS in Group 1 vs. Group 3
  4. b denotes the comparison of patients with ARDS in Group 2 vs. Group 3
  5. c denotes the comparison of patients with ICU in Group 1 vs. Group 3
  6. d denotes the comparison of patients with ICU in Group 2 vs. Group 3